Skip to search formSkip to main contentSkip to account menu

ABT 888

Known as: ABT-888, ABT888, PARP-1 inhibitor ABT-888 
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

veliparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).
1015 Background: Veliparib (ABT-888) is an oral, potent small molecule inhibitor of poly-ADP-ribose polymerase (PARP). The… 
2013
2013
Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
2013
2013
Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
2012
2012
A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer…
3054 Background: Veliparib (ABT-888) is an oral, potent inhibitor of PARP 1/2. Preclinically, PARP inhibitors have activity in… 
Highly Cited
2011
Highly Cited
2011
Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
Background Poly(ADP-ribose) polymerase (PARP)facilitates DNA repair and PARP inhibitors may potentiate the effect of DNA-damaging… 
2011
2011
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
3041 Background: Veliparib is a potent, oral inhibitor of PARP-1 and PARP-2. We previously reported phase I results of veliparib… 
2011
2011
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in…
3000 Background: The nuclear enzyme PARP is essential in recognition and repair of DNA damage. In preclinical models, PARP… 
2011
2011
A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.
3502 Background: Inhibitors of poly(ADP-ribose) polymerase (PARP), such as ABT-888 are potent sensitizing agents for, and have… 
2010
2010
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
3000 Background: ABT-888 is a potent, oral inhibitor of PARP-1 and PARP-2. In preclinical studies, ABT-888 enhances the… 
2008
2008
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
PurposeABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)